RDIF and ChemRar announce increased production of Avifavir for treatment of coronavirus and begin export deliveries
RDIF and ChemRar have produced the first 100,000 courses of Avifavir
In June Avifavir was delivered across Russia’s 35 regions
More than 50 countries have expressed interest in importing Avifavir
Moscow, July 2, 2020 –
The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and ChemRar Group
produced the first 100,000 courses of the Russian coronavirus drug Avifavir in June, significantly exceeding initially planned production levels of 60,000 courses.
In June, the drug
was delivered across Russia’s 35 regions and to the Republic of Belarus.
Agreement
has also been reached for deliveries of Avifavir to the Republic of Kazakhstan in the near future. In total, more than 100,000 courses will be produced in July.
The joint venture established by RDIF and ChemRar Group
provided an additional opportunity to increase production capacity threefold, up to 300,000 courses per month, which will satisfy domestic demand for Avifavir in the Russian Federation and enable the start of supplies to the international market.
On May 29, 2020, Avifavir
received a registration certificate from Russia’s Ministry of Health and became the first Favipiravir-based drug in the world approved for the treatment of COVID-19.
On June 3, 2020, the Ministry of Health
included Avifavir in the latest seventh edition of the guidelines for the prevention, diagnosis and treatment of new coronavirus infection COVID-19.
Avifavir has proven effective in clinical trials, disrupting the reproduction mechanisms of coronavirus.
RDIF and ChemRar
have seen significant demand for the drug from abroad. In particular, negotiations are underway on the supply of Avifavir to a number of Latin American countries.
In addition, CIS countries, the Middle East and other global regions have expressed interest in acquiring Avifavir.